Autoantibodies to intracellular antigens: Generation and pathogenetic role

Autoimmunity Reviews

Volumn 10, Issue 8, 2011, Pages 503-508

  Racanelli, Vito ^a   Prete, Marcella ^a   Musaraj, Gerta ^a   Dammacco, Franco ^a   Perosa, Federico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Autoantibodies; Epigenetic modification; Intracellular antigen; Intracellular immunity; Molecular mimicry; Pathogenicity

Indexed keywords

AUTOANTIBODY; CELL ANTIGEN; PROTEIN; PROTEIN TRIM21; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; APOPTOSIS; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; DIAGNOSTIC VALUE; EPIGENETICS; HUMAN; IDIOPATHIC DISEASE; IMMUNOREGULATION; MIXED CONNECTIVE TISSUE DISEASE; MOLECULAR MIMICRY; MYOPATHY; NONHUMAN; PATHOGENESIS; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ANIMALS; ANTIBODY FORMATION; APOPTOSIS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; EPIGENESIS, GENETIC; HUMANS; INTRACELLULAR SPACE; ORGAN SPECIFICITY; PROGNOSIS;

EID: 79957633257     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.03.001     Document Type: Review

References (84)

1. Cooper M.D., Herrin B.R. How did our complex immune system evolve?. Nat Rev Immunol 2010, 10:2-3.
2. Goodnow C.C., Sprent J., Fazekas de St G.B., Vinuesa C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435:590-597.
3. Zerrahn J., Held W., Raulet D.H. The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 1997, 88:627-636.
4. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997, 84:223-243.
5. Kronenberg M., Rudensky A. Regulation of immunity by self-reactive T cells. Nature 2005, 435:598-604.
6. Lleo A., Invernizzi P., Gao B., Podda M., Gershwin M.E. Definition of human autoimmunity - autoantibodies versus autoimmune disease. Autoimmun Rev 2009, 9:A259-A266.
7. Davidson A., Diamond B. Autoimmune diseases. N Engl J Med 2001, 345:340-350.
8. Racanelli V., Prete M., Minoia C., Favoino E., Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 2008, 7:352-358.
9. Nussinovitch U., Shoenfeld Y. The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease. Clin Rev Allergy Immunol 2011, 10.1007/s12016-010-8229-8.
10. Nussinovitch U., Shoenfeld Y. Anti-troponin autoantibodies and the cardiovascular system. Heart 2010, 96:1518-1524.
11. Burek C.L. Autoimmune thyroiditis research at Johns Hopkins University. Immunol Res 2010, 47:207-215.
12. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
13. Naparstek Y., Plotz P.H. The role of autoantibodies in autoimmune disease. Annu Rev Immunol 1993, 11:79-104.
14. Edelson R.L. Pemphigus-decoding the cellular language of cutaneous autoimmunity. N Engl J Med 2000, 343:60-61.
15. Yamamoto Y., Aoyama Y., Shu E., Tsunoda K., Amagai M., Kitajima Y. Anti-desmoglein 3 (Dsg3) monoclonal antibodies deplete desmosomes of Dsg3 and differ in their Dsg3-depleting activities related to pathogenicity. J Biol Chem 2007, 282:17866-17876.
16. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676.
17. Toh B.H., Alderuccio F. Pernicious anaemia. Autoimmunity 2004, 37:357-361.
18. Toltl L.J., Arnold D.M. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol 2011, 152:52-60.
19. Michel M., Chanet V., Dechartres A., Morin A.S., Piette J.C., Cirasino L., et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 2009, 114:3167-3172.
20. Gehrs B.C., Friedberg R.C. Autoimmune hemolytic anemia. Am J Hematol 2002, 69:258-271.
21. Meriggioli M.N. Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci 2009, 26:94-108.
22. Yu R.K., Ariga T., Kohriyama T., Kusunoki S., Maeda Y., Miyatani N. Autoimmune mechanisms in peripheral neuropathies. Ann Neurol 1990, 27:S30-S35. Suppl.
23. Arad A., Proulle V., Furie R.A., Furie B.C., Furie B. Beta 2 glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011, 10.1182/blood-2010-08-300715.
24. de Groot P.G. Mechanisms of anti-phospholipid antibody formation and action. Thromb Res 2011, 127:S40-S42.
25. Edwards J.C., Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 1998, 37:126-130.
26. Uysal H., Nandakumar K.S., Kessel C., Haag S., Carlsen S., Burkhardt H., et al. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol Rev 2010, 233:9-33.
27. Hoffman R.W., Maldonado M.E. Immune pathogenesis of mixed connective tissue disease: a short analytical review. Clin Immunol 2008, 128:8-17.
28. Routsias J.G., Tzioufas A.G. B-cell epitopes of the intracellular autoantigens Ro/SSA and La/SSB: tools to study the regulation of the autoimmune response. J Autoimmun 2010, 35:256-264.
29. Szalat R., Ghillani-Dalbin P., Jallouli M., Amoura Z., Musset L., Cacoub P., et al. Anti-NuMA1 and anti-NuMA2 (anti-HsEg5) antibodies: clinical and immunological features: a propos of 40 new cases and review of the literature. Autoimmun Rev 2010, 9:652-656.
30. Nihtyanova S.I., Denton C.P. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010, 6:112-116.
31. Gunawardena H., Betteridge Z.E., McHugh N.J. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology Oxf 2009, 48:607-612.
32. Anzilotti C., Pratesi F., Tommasi C., Migliorini P. Peptidylarginine deiminase 4 and citrullination in health and disease. Autoimmun Rev 2010, 9:158-160.
33. Chen M., Kallenberg C.G. ANCA-associated vasculitides-advances in pathogenesis and treatment. Nat Rev Rheumatol 2010, 6:653-664.
34. Schilder A.M. Wegener's Granulomatosis vasculitis and granuloma. Autoimmun Rev 2010, 9:483-487.
35. Gershwin M.E., Mackay I.R. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 2008, 47:737-745.
36. Czompoly T., Olasz K., Nyarady Z., Simon D., Bovari J., Nemeth P. Detailed analyses of antibodies recognizing mitochondrial antigens suggest similar or identical mechanism for production of natural antibodies and natural autoantibodies. Autoimmun Rev 2008, 7:463-467.
37. Tzioufas A.G., Routsias J.G. Idiotype, anti-idiotype network of autoantibodies: pathogenetic considerations and clinical application. Autoimmun Rev 2010, 9:631-633.
38. Rapoport B., McLachlan S.M. Thyroid autoimmunity. J Clin Invest 2001, 108:1253-1259.
39. Frisoni L., McPhie L., Colonna L., Sriram U., Monestier M., Gallucci S., et al. Nuclear autoantigen translocation and autoantibody opsonization lead to increased dendritic cell phagocytosis and presentation of nuclear antigens: a novel pathogenic pathway for autoimmunity?. J Immunol 2005, 175:2692-2701.
40. Hansen M.H., Nielsen H.V., Ditzel H.J. Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol 2002, 169:2701-2711.
41. Ohishi K., Kanoh M., Shinomiya H., Hitsumoto Y., Utsumi S. Complement activation by cross-linked B cell-membrane IgM. J Immunol 1995, 154:3173-3179.
42. Jefferis R., Pound J., Lund J., Goodall M. Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects. Review article. Ann Biol Clin Paris 1994, 52:57-65.
43. Ando T., Davies T.F. Monoclonal antibodies to the thyrotropin receptor. Clin Dev Immunol 2005, 12:137-143.
44. Matucci-Cerinic M., Steen V., Nash P., Hachulla E. The complexity of managing systemic sclerosis: screening and diagnosis. Rheumatology Oxf 2009, 48(Suppl. 3):iii8-13.
45. Coutinho A., Kazatchkine M.D., Avrameas S. Natural autoantibodies. Curr Opin Immunol 1995, 7:812-818.
46. Dighiero G. Natural autoantibodies, tolerance, and autoimmunity. Ann NY Acad Sci 1997, 815:182-192.
47. Casali P., Schettino E.W. Structure and function of natural antibodies. Curr Top Microbiol Immunol 1996, 210:167-179.
48. Shlomchik M.J., Marshak-Rothstein A., Wolfowicz C.B., Rothstein T.L., Weigert M.G. The role of clonal selection and somatic mutation in autoimmunity. Nature 1987, 328:805-811.
49. Shlomchik M., Mascelli M., Shan H., Radic M.Z., Pisetsky D., Marshak-Rothstein A., et al. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J Exp Med 1990, 171:265-292.
50. Radic M.Z., Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol 1994, 12:487-520.
51. Casciola-Rosen L., Andrade F., Ulanet D., Wong W.B., Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999, 190:815-826.
52. Fransen J.H., Hilbrands L.B., Ruben J., Stoffels M., Adema G.J., van der Vlag J., et al. Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17. Arthritis Rheum 2009, 60:2304-2313.
53. Fehr E.M., Kierschke S., Max R., Gerber A., Lorenz H.M., Schiller M. Apototic cell-derived membrane vesicles induce CD83 expression on human mdDC. Autoimmunity 2009, 42:322-324.
54. Munoz L.E., Lauber K., Schiller M., Manfredi A.A., Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010, 6:280-289.
55. Howard O.M., Dong H.F., Yang D., Raben N., Nagaraju K., Rosen A., et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002, 196:781-791.
56. Suber T.L., Casciola-Rosen L., Rosen A. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol 2008, 4:201-209.
57. Rosen A., Casciola-Rosen L. Clearing the way to mechanisms of autoimmunity. Nat Med 2001, 7:664-665.
58. Suber T., Rosen A. Apoptotic cell blebs: repositories of autoantigens and contributors to immune context. Arthritis Rheum 2009, 60:2216-2219.
59. Renaudineau Y., Garaud S., Le D.C., onso-Ramirez R., Daridon C., Youinou P. Autoreactive B cells and epigenetics. Clin Rev Allergy Immunol 2010, 39:85-94.
60. Dubroff L.M., Reid R.J. Hydralazine-pyrimidine interactions may explain hydralazine-induced lupus erythematosus. Science 1980, 208:404-406.
61. Lee B.H., Yegnasubramanian S., Lin X., Nelson W.G. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem 2005, 280:40749-40756.
62. Quddus J., Johnson K.J., Gavalchin J., Amento E.P., Chrisp C.E., Yung R.L., et al. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 1993, 92:38-53.
63. Strickland F.M., Richardson B.C. Epigenetics in human autoimmunity. Epigenetics in autoimmunity - DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity 2008, 41:278-286.
64. Ciavatta D.J., Yang J., Preston G.A., Badhwar A.K., Xiao H., Hewins P., et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest 2010, 120:3209-3219.
65. Xiao C., Srinivasan L., Calado D.P., Patterson H.C., Zhang B., Wang J., et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008, 9:405-414.
66. Routsias J.G., Vlachoyiannopoulos P.G., Tzioufas A.G. Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response. Crit Rev Clin Lab Sci 2006, 43:203-248.
67. McClain M.T., Heinlen L.D., Dennis G.J., Roebuck J., Harley J.B., James J.A. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005, 11:85-89.
68. Mahler M., Mierau R., Schlumberger W., Bluthner M. A population of autoantibodies against a centromere-associated protein A major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1. J Mol Med 2001, 79:722-731.
69. Lunardi C., Bason C., Navone R., Millo E., Damonte G., Corrocher R., et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000, 6:1183-1186.
70. Mahler M., Bluthner M., Pollard K.M. Advances in B-cell epitope analysis of autoantigens in connective tissue diseases. Clin Immunol 2003, 107:65-79.
71. Perosa F., Favoino E., Caragnano M.A., Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006, 107:1070-1077.
72. Perosa F., Vicenti C., Racanelli V., Leone P., Valentini G., Dammacco F. The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3). Clin Immunol 2010, 137:60-73.
73. Alarcon-Segovia D., Ruiz-Arguelles A., Fishbein E. Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors. Nature 1978, 271:67-69.
74. Ruiz-Arguelles A., Perez-romano B., Llorente L., arcon-Segovia D., Castellanos J.M. Penetration of anti-DNA antibodies into immature live cells. J Autoimmun 1998, 11:547-556.
75. Madaio M.P., Yanase K. Cellular penetration and nuclear localization of anti-DNA antibodies: mechanisms, consequences, implications and applications. J Autoimmun 1998, 11:535-538.
76. Abedi-Valugerdi M., Hu H., Moller G. Mercury-induced anti-nucleolar autoantibodies can transgress the membrane of living cells in vivo and in vitro. Int Immunol 1999, 11:605-615.
77. Matsumura S., Van Test W.J. article sample title placed here. Hepatology 2004, 39:1415-1422.
78. Lisi S., Sisto M., Lofrumento D., Frassanito M.A., Caprio S., Romano M.L., et al. Regulation of mRNA caspase-8 levels by anti-nuclear autoantibodies. Clin Exp Med 2010, 10:199-203.
79. Yanase K., Smith R.M., Puccetti A., Jarett L., Madaio M.P. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest 1997, 100:25-31.
80. Song Y.C., Sun G.H., Lee T.P., Huang J.C., Yu C.L., Chen C.H., et al. Arginines in the CDR of anti-dsDNA autoantibodies facilitate cell internalization via electrostatic interactions. Eur J Immunol 2008, 38:3178-3190.
81. Jang J.Y., Jeong J.G., Jun H.R., Lee S.C., Kim J.S., Kim Y.S., et al. A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity. Cell Mol Life Sci 2009, 66:1985-1997.
82. Mallery D.L., McEwan W.A., Bidgood S.R., Towers G.J., Johnson C.M., James L.C. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A 2010, 107:19985-19990.
83. Espinosa A., Dardalhon V., Brauner S., Ambrosi A., Higgs R., Quintana F.J., et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 2009, 206:1661-1671.
84. Espinosa A., Zhou W., Ek M., Hedlund M., Brauner S., Popovic K., et al. The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 2006, 176:6277-6285.